Differential gene expression in skeletal muscle after induction of heart failure: Impact of cytokines on protein phosphatase 2A expression

Molecular Genetics and Metabolism

Volumn 80, Issue 1-2, 2003, Pages 262-271

  Kränkel, Nicolle ^a   Adams, Volker ^a   Gielen, Stephan ^a   Linke, Axel ^a   Erbs, Sandra ^a   Schuler, Gerhard ^a   Hambrecht, Rainer ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Chronic heart failure; Differential gene expression; Inflammatory cytokines; PP2A; Skeletal muscle; Suppression subtractive hybridization

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ALPHA ACTIN; BRIDGING INTEGRATOR PROTEIN 1; CELL NUCLEUS RECEPTOR; CENTAURIN ALPHA2; CHROMOSOME PROTEIN; COMPLEMENT COMPONENT C1Q; CYTOCHROME C; CYTOKINE; DIMETHYLANILINE MONOOXYGENASE; GAMMA INTERFERON; GLYCOGEN PHOSPHORYLASE; INTERLEUKIN 1BETA; MESSENGER RNA; MYOSIN BINDING PROTEIN C; MYOSIN HEAVY CHAIN; MYOSIN LIGHT CHAIN; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN; PROTEIN MSS4; PROTEIN SMARCA2; TROPOMYOSIN; TROPONIN C; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR ADHESION PROTEIN 1;

ADULT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; ENERGY METABOLISM; GENE CONTROL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE SEQUENCE; HEART FAILURE; HUMAN; HUMAN TISSUE; HYBRIDIZATION; MALE; MOLECULAR CLONING; MUSCLE BIOPSY; MUSCLE CONTRACTILITY; MYOBLAST; NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SKELETAL MUSCLE; STATISTICAL SIGNIFICANCE; UPREGULATION;

ANIMALIA; MUSCULUS;

EID: 0142089727     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-7192(03)00132-X     Document Type: Article

References (71)

1. Cohn J.N., Bristow M.R., Chien K.R., Colucci W.S., Frazier O.H., Leinwand L.A., Lorell B.H., Moss A.J., Sonnenblick E.H., Walsh R.A., Mockrin S.C., Reinlib L. Report of the national heart, lung, and blood institute special emphasis panel on heart failure research. Circulation. 95:1997;766-770.
2. Szlachcic J., Massie B.M., Kramer B.L., Topic N., Tubau J. Correlates and prognostic implication of exercise capacity in chronic heart failure. Am. J. Cardiol. 55:1985;1037-1042.
3. Higginbotham M.B., Morris K.G., Conn E.H., Coleman R.E., Cobb F.R. Determinants of variable exercise performance among patients with severe left ventricular dysfunction. Am. J. Cardiol. 51:1983;52-60.
4. Clark A., Coats A. Mechanisms of exercise intolerance in cardiac failure: abnormalities of skeletal muscle and pulmonary function. Curr. Opin. Cardiol. 9:1994;305-314.
5. Schaufelberger M., Eriksson B.O., Grimby G., Held P., Swedberg K. Skeletal muscle alterations in patients with chronic heart failure. Eur. Heart J. 18:1997;971-980.
6. Harrington D., Coats A.J.S. Mechanisms of exercise intolerance in congestive heart failure. Curr. Opin. Cardiol. 12:1997;224-232.
7. Sullivan M.J., Green H.J., Cobb F.R. Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. Circulation. 81:1990;518-527.
8. Massie B.M., Simonini A., Sahgal P., Wells L., Dudley G.A. Relation of systemic and local muscle exercise capacity to skeletal muscle characteristics in men with congestive heart failure. J. Am. Coll. Cardiol. 27:1996;140-151.
9. Hambrecht R., Fiehn E., Yu J., Niebauer J., Weigl C., Hilbrich L., Adams V., Riede U., Schuler G. Effects of endurance training on mitochondrial ultrastructure and fiber type distribution in skeletal muscle of patients with stable chronic heart failure. J. Am. Coll. Cardiol. 29:1997;1067-1073.
10. 2+-ATPase gene expression in congestive heart failure. Circ. Res. 81:1997;703-710.
11. Cohen R.A., Shepherd J.T., Vanhoutte P.M. Inhibitory role of the endothelium in the response of isolated coronary arteries to platelets. Science. 221:1983;273-274.
12. Vescovo G., Volterrani M., Zennaro R., Sandri M., Ceconi C., Lorusso R., Ferrari R., Ambrosio G.B., dalla Libera L. Apoptosis in the skeletal muscle of patients with heart failure: investigation of clinical and biochemical changes. Heart. 84:2000;431-437.
13. Adams V., Jiang H., Yu J., Möbius-Winkler S., Fiehn E., Linke A., Weigl C., Schuler G., Hambrecht R. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J. Am. Coll. Cardiol. 33:1999;959-965.
14. Knöll R., Zimmermann R., Arras M., Schaper W. Characterization of differentially expressed genes following brief cardiac ischemia. Biochem. Biophys. Res. Commun. 221:1996;402-407.
15. Hufton S.E., Moerkerk P.T., Brandwijk R., de Bruine A.P., Arends J.W., Hoogenboom H.R. A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization. FEBS Lett. 463:1999;77-82.
16. Krapfenbauer K., Yoo B.C., Kim S.H., Cairns N., Lubec G. Differential display reveals downregulation of the phospholipid transfer protein (PLTP) at the mRNA level in brains of patients with down syndrome. Life Sci. 68:2001;2169-2179.
17. Hagiwara K., Yamaguchi A., Tsuchiya N., Kitamura S., Iwadare J., Sahara R., Yamamoto K., Tokunaga K. Identification of genes upregulated in the inflamed colonic lesions of Crohn's disease. Biochem. Biophys. Res. Commun. 283:2001;130-135.
18. Zuber J., Tchernitsa O.I., Hinzmann B., Schmitz A.C., Grips M., Hellriegel M., Sers C., Rosenthal A., Schäfer R. A genome-wide survey of RAS transformation targets. Nat. Genet. 24:2000;144-152.
19. von Stein O.D., Thies W.G., Hofmann M. A high throughput screening for rarely transcribed differentially expressed genes. Nucleic Acids Res. 25:1997;2598-2602.
20. Chang D.D., Park N.H., Denny C.T., Nelson S.F., Pe M. Characterization of transformation related genes in oral cancer cells. Oncogene. 16:1998;1921-1930.
21. Bergström J. Muscle electrolytes in man. Scand. J. Clin. Lab. Invest. 68:1962;7-110.
22. Adams V., Nehrhoff B., Späte U., Linke A., Schulze P.C., Baur A., Gielen S., Hambrecht R., Schuler G. Induction of iNOS-expression in skeletal muscle by IL-1β and NFκB activation: an in vitro and in vivo study. Cardiovasc. Res. 54:2002;95-104.
23. Henriksen P.A., Kotelevtsev Y. Application of gene expression profiling to cardiovascular disease. Cardiovasc. Res. 54:2002;16-24.
24. Simonini A., Long C.S., Dudley G.A., Yue P., McElhinny J., Massie B.M. Heart failure in rats causes changes in skeletal muscle morphology and gene expression that are not explained by reduced activity. Circ. Res. 79:1996;128-136.
25. Sullivan M.J., Duscha B.D., Klitgaard H., Kraus W.E., Cobb F.R., Saltin B. Altered expression of myosin heavy chain in human skeletal muscle in chronic heart failure. Med. Sci. Sports Exerc. 29:1997;860-866.
26. Maier G.D., Wright M.A., Lozano Y., Djordjevic A., Matthews J.P., Young M.R. Regulation of cytoskeletal organization in tumor cells by protein phosphatases-1 and -2A. Int. J. Cardiol. 61:1995;54-61.
27. Sontag E. Protein phosphatase 2A: the trojan horse of cellular signaling. Cell. Signal. 13:2001;7-16.
28. Jamssens V., Goris J. Protein phosphatase 2A: a highly related family of serine/threonine phosphatases implicated in cell growth and signaling. Biochem. J. 353:2001;417-439.
29. Zolnierowicz S. Type 2A protein phosphatase, the complex regulator of numerous signaling pathways. Biochem. Pharmacol. 60:2000;1225-1235.
30. Klumpp S., Krieglstein J. Serine/threonine protein phosphatases in apoptosis. Curr. Opin. Pharmacol. 2:2002;458-462.
31. Neumann J., Maas R., Boknik P., Jones L.R., Zimmermann N., Scholz H. Pharmacological characterization of protein phosphatase activities in preparations from failing human hearts. J. Pharmacol. Exp. Ther. 289:1999;188-193.
32. Tehrani M.A., Mumby M.C., Kamibayashi C. Identification of a novel protein phosphatase 2A regulatory subunit highly expressed in muscles. J. Biol. Chem. 271:1996;5164-5170.
33. Vescovo G., Zennaro R., Sandri M., Carraro U., Leprotti C., Ceconi C., Ambrosio G.B., Dalla-Libera L. Apoptosis of skeletal muscle myofibers and interstitial cells in experimental heart failure. J. Mol. Cell. Cardiol. 30:1998;2449-2459.
34. Chiang C.W., Harris G., Ellig C., Masters S.C., Subramanian R., Shenolikar S., Wadzinski B.E., Yang E. Protein phosphatase 2A activates the proapoptotic function of BAD in interleukin-3-dependent lymphoid cells by a mechanism requiring 14-3-3 dissociation. Blood. 97:2001;1289-1297.
35. Ruvolo P.P., Deng X., Ito T., Carr B.K., May W.S. Ceramide induces Bcl2 dephosphorylation via a mechanism involving mitochondrial PP2A. J. Biol. Chem. 274:1999;20296-20300.
36. Reed J.C., Pasternostro G. Postmitochondrial regulation of apoptosis during heart failure. Proc. Natl. Acad. Sci. 96:1999;7614-7616.
37. Datta S.R., Brunet A., Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev. 13:1999;2905-2927.
38. Ruvolo P.P. Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol. Res. 47:2003;383-392.
39. Vescovo G., Ravara B., Gobbo V., Sandri M., Angelini A., Della Barbera M., Dona M., Peluso G., Calvani M., Mosconi L., Dalla-Libera L. L-Carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure. Am. J. Physiol. Cell Physiol. 283:2002;C802-C810.
40. Kremmer E., Ohst K., Kiefer J., Brewis N., Walter G. Separation of PP2A core enzyme and holoenzyme with monoclonal antibodies against the regulatory A subunit: abundant expression of both forms in cells. Mol. Cell. Biol. 17:1997;1692-1701.
41. Turowski P., Favre B., Campbell K.S., Lamb N.J.C., Hemmings B.A. Modulation of the enzymatic properties of protein phosphatase 2A catalytic subunit by the recombinant 65-kDa regulatory subunit PR65alpha. Eur. J. Biochem. 248:1997;200-208.
42. Agostinis P., Goris J., Pinna L.A., Marchiori F., Perich J.W., Meyer H.E., Merlevede W. Synthetic peptides as model substrates for the study of the specificity of the polycation-stimulated protein phosphatases. Eur. J. Biochem. 189:1990;235-241.
43. Czegielska A., Shaffer S., Derua R., Goris J., Virshup D.M. Different oligomeric forms of protein phosphatase 2A activate and inhibit simian virus 40 DNA replication. Mol. Cell. Biol. 14:1994;416-423.
44. Svennilson J., Sandberg-Nordqvist A., Aperia A. Age-dependent expression of protein phosphatase 2A in the developing rat kidney. Pediatr. Nephrol. 13:1999;800-805.
45. Zhou J., Pham H.T., Walter G. The formation and activity of PP2A holoenzymes does not depend on the isoform of the catalytic subunit. J. Biol. Chem. 278:2003;8617-8622.
46. Arino J., Woon C.W., Brautigan D.L., Miller T.B., Johnson G.L. Human liver phosphatase 2A: cDNA and amino acid sequence of two catalytic subunit isotypes. Proc. Natl. Acad. Sci. USA. 85:1988;4252-4256.
47. Chen M.H., Antoni L., Tazi-Ahnini R., Cork M., Ward S.J., Bavik C.O. Identification of known and novel genes whose expression is regulated by endogenous retinoic acid during early embryonic development of the mouse. Mech. Dev. 114:2002;205-212.
48. Alberts B.S., Thorburn A.M., Shenolikar S., Mumby M.C., Feramisco J.R. Regulation of cell cycle progression and nuclear affinity of the retinoblastoma protein by protein phosphatases. Proc. Natl. Acad. Sci. USA. 90:1993;388-392.
49. Kikuchi K., Kitamura K., Kakinoki Y., Nakamura K., Matsuzawa S., Saadat M., Mizuno Y. Gene expressions and activities of protein phosphatases 1 alpha, 2A and 2C in hepatocarcinogenesis and regeneration after partial hepatectomy. Cancer Detect. Prev. 21:1997;36-43.
50. Vogelsberg-Ragaglia V., Schuck T., Trojanowski J.Q., Lee V.M. PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp. Neurol. 168:2001;402-412.
51. Torre-Amione G., Kapadia S.R., Benedict C., Oral H., Young J.B., Mann D.L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol. 27:1996;1201-1206.
52. Wolff R.A., Dobrowsky R.T., Bielawska A., Obeid L.M., Hannun Y.A. Role of ceramide-activated protein phosphatase in ceramide-mediated signal transduction. J. Biol. Chem. 269:1994;19605-19609.
53. Reyes J.G., Robayna I.G., Delgado P.S., Gonzales I.H., Aguiar J.Q., Rosas F.E., Fanjul L.F., Galarreta G.M. c-Jun is a downstream target for ceramide-activated protein phosphatase in A431 cells. J. Biol. Chem. 271:1996;21375-21380.
54. Daibo G.S., Obeid L.M., Hannun Y.A. Tumor necrosis factor-alpha (TNF-alpha) signal transduction through ceramide. Dissociation of growth inhibitory effects of TNF-alpha from activation of nuclear factor-kappa B. J. Biol. Chem. 268:1993;17762-17766.
55. Vescovo G., Serafini F., Facchin L., Tenderini P., Carraro U., Dalla-Libera L., Catani C., Ambrosio G.B. Specific changes in skeletal muscle myosin heavy chain composition in cardiac failure: differences compared with disuse atrophy as assessed on microbiopsies by high resolution electrophoresis. Heart. 76:1996;337-343.
56. Lynch N.J., Reid K.B., van der Berg R.H., Daha M.R., Leigh L.A., Ghebrehiwet B., Lim W.B., Schwaeble W.J. Characterisation of the rat and mouse homologues of gC1qBP, a 33. kDa glycoprotein that binds to the globular 'heads' of C1q FEBS Lett. 418:1997;111-114.
57. Jackson T.R., Kearns B.G., Theibert A.B. Cytohesins and centaurins: mediators of PI 3-kinase-regulated Arf signaling. Trends Biochem. Sci. 25:2000;489-495.
58. Burton J.L., Burns M.E., Gatti E., Augustine G.J., De Camilli P. Specific interactions of Mss4 with members of the Rab GTPase subfamily. EMBO J. 13:1994;5547-5558.
59. Baily P., Downes M., Lau P., Harris J., Chen S.L., Hamamori Y., Sartorelli V., Muscat G.E. The nuclear receptor corepressor N-CoR regulates differentiation: N-CoR directly interacts with MyoD. Mol. Endocrinol. 13:1999;1155-1168.
60. Smith D.J., Salmi M., Bono P., Hellman J., Leu T., Jalkanen S. Cloning of vascular adhesion protein 1 reveals a novel multifunctional adhesion molecule. J. Exp. Med. 188:1998;17-27.
61. Boomsma F., de Kam P.J., Tjeerdsma G., van der Meiracker A.H., van Veldhuisen D.J. Plasma semicarbazide-sensitive amine oxidase (SSAO) is an independent prognostic marker for mortality in chronic heart failure. Eur. Heart J. 21:2000;1859-1863.
62. Patzak D., Zhuchenko O., Lee C.C., Wehnert M. Identification, mapping, and genomic structure of a novel X-chromosomal human gene (SMPX) encoding a small muscular protein. Hum. Genet. 105:1999;506-512.
63. Simonini A., Massie B.M., Long C.S., Qi M., Samarel A.M. Alterations in skeletal muscle gene expression in the rat with chronic congestive heart failure. J. Mol. Cell. Cardiol. 28:1996;1683-1691.
64. Ridley A. What initiates actin polymerization? Genome Biol. 1:2000;102.1-102.4.
65. Winegrad S. Cardiac myosin binding protein C. Circ. Res. 84:1999;1117-1126.
66. Watkins H., Conner D., Thierfelder L., Jarcho J.A., MacRae C., McKenna W.J., Maron B.J., Seidman J.G., Seidman C.E. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat. Genet. 11:1995;434-437.
67. Schwartz K., Mercadier J. Molecular and cellular biology of heart failure. Curr. Opin. Cardiol. 11:1996;227-236.
68. Wechsler-Reya R.J., Elliott K.J., Prendergast G.C. A role for the putative tumor suppressor Bin1 in muscle cell differentiation. Mol. Cell. Biol. 18:1998;566-575.
69. Dunn S.E., Burns J.L., Michel R.N. Calcineurin is required for skeletal muscle hypertrophy. J. Biol. Chem. 274:1999;21908-21912.
70. Nagano M., Kato M., Nagai M., Yang J. Protective effect of ACE- and kinase-inhibitor on the onset of cardiomyopathy. Basic Res. Cardiol. 86:1991;187-195.
71. Krause E.G., Will H., Bohm M., Wollenberger A. The assay of glycogen phosphorylase in human blood serum and its application to the diagnosis of myocardial infarction. Clin. Chim. Acta. 58:1975;145-154.